NLA Recommendations & Statements

The NLA held a consensus conference in January 2011 to bring together experts on inflammatory markers and advanced lipoprotein testing for the generation of an NLA statement of clinical guidance regarding the utility of various biomarkers. The panel reviewed apolipoprotein B (Apo B), C-reactive protein (CRP), high-density lipoprotein (HDL) subfractions, lipoprotein-associated phospholipase A2 (Lp-PLA2), low-density lipoprotein (LDL) subfractions, low-density lipoprotein particle number/concentration (LDL-P), and lipoprotein (a) (Lp(a)).



Publish Date:
October 4, 2011 - 12:00pm
Last Updated: Jan, 2017

Adapted from an article in the Journal of Clinical Lipidology (JCL) titled, The Importance of Non-HDL Cholesterol Reporting in Lipid Management1



Publish Date:
September 8, 2011 - 12:00am
Last Updated: Jan, 2017

In connection with the Familial Hypercholesterolemia ("FH") initiative of the Foundation of the National Lipid Association, the NLA held a consensus conference in January 2011 to bring together experts on FH for the generation of an NLA statement of clinical guidance regarding the diagnosis and treatment FH. The link above provides the Executive Summary of the NLA expert panel, published in the June 2011 edition of the Journal of Clinical Lipidology.



Publish Date:
June 1, 2011 - 12:00am
Last Updated: Jan, 2017